Possible clinical outcome measures for clinical trials in patients with multiple sclerosis
Open Access
- 23 June 2010
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 3 (4), 229-239
- https://doi.org/10.1177/1756285610374117
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease with both clinical and pathological heterogeneity. The complexity of the MS population has offered challenges to the measurement of MS disease progression in therapeutic trials. The current standard clinical outcome measures are relapse rate, Expanded Disability Severity Scale (EDSS), and the MS Functional Composite (MSFC). These measures each have strengths and some weakness. Two additional measures, the six-minute walk and accelerometry, show promise in augmenting current measures. MS therapeutics is a quickly advancing field which requires sensitive clinical outcome measures that can detect small changes in disability that reliably reflect long-term changes in sustained disease progression in a complex population. A single clinical outcome measure of sustained disease progression may remain elusive. Rather, an integration of current and new outcome measures may be most appropriate and utilization of different measures depending on the MS population and stage of the disease may be preferred.Keywords
This publication has 93 references indexed in Scilit:
- Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophyNeurology, 2010
- Outcome measurement in multiple sclerosis: detection of clinically relevant improvementMultiple Sclerosis Journal, 2010
- Impact of multiple sclerosis relapses on progression diminishes with timeNeurology, 2009
- Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSSJournal of the Neurological Sciences, 2009
- Physical activity and quality of life in multiple sclerosis: Intermediary roles of disability, fatigue, mood, pain, self-efficacy and social supportPsychology, Health & Medicine, 2008
- Evaluation of response of multiple sclerosis (MS) relapse to oral high‐dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status ScaleEuropean Journal of Neurology, 2008
- Validation of the Functional Assessment of Multiple Sclerosis quality of life instrumentNeurology, 1996
- Defining the clinical course of multiple sclerosisNeurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Rating neurologic impairment in multiple sclerosisNeurology, 1983